Maurizio Fava, MD
Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
Original Research
Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in MDD
May 30, 2022
Altered glutamatergic neurotransmission has been implicated in the pathogenesis of depression. This phase 3 trial evaluated the efficacy and safety of AXS-05 (dextromethorphan-bupropion) in the treatment of major depressive...
Original Research
Adjunctive Pimavanserin and Sleep/Wakefulness in MDD
December 1, 2020
Adjunctive pimavanserin can reduce depressive symptoms and improve function in patients with major depression and inadequate antidepressant response. This analysis evaluated the effects of adjunctive pimavanserin on sleep/wakefulness disturbances.
Original Research
Effect of SPN-812 (Viloxazine Extended-Release) on QTc Interval
October 13, 2020
This double-blind, randomized, crossover study investigated the effects of a supratherapeutic dose of SPN-812, a drug currently under investigation as a treatment for ADHD, on cardiac repolarization (QTc) in...
Original Research
Ganaxolone for Persistent Depression
June 9, 2020
Postmenopausal women may be deficient in the neuroactive steroid allopregnanolone. This study examined oral ganaxolone, an allopregnanolone analog, as augmentation therapy in postmenopausal women with inadequate response to traditional...
Original Research
Ziprasidone Augmentation of Escitalopram for Cognition
July 25, 2017
Cognitive deficits are common in depression, but studies suggest that cognitive dysfunction is difficult to treat with antidepressants. Can adding an atypical antipsychotic medication to antidepressant treatment help lessen...
